



โรงพยาบาลกรุงเทพ
BANGKOK HOSPITAL



โรงพยาบาลกรุงเทพ
BANGKOK HOSPITAL

2 Soi Soonvijai 7, New Petchburi Rd., Bangkok 10310

Tel. 0-2310-3000 Fax 0-2318-1546

www.bangkokhospital.com, www.wattanosoth.com



Wattanosoth
Cancer Registry
2012

Table of Contents

Message from CEO

01 01

Message from Director

02 02

Wattanosoth Doctor Team

03 03

Cancer Registry 2012 : Abstract

04 04

Annual Cancer Registry 2012

05 05

*Distribution by Age and Gender, The 10 Leading Site of Cancer,
Patient Category, Method of Diagnosis, Staging, Type of Treatment,
Patient Follow up, Patient Nationality*

Review of Breast Cancer

14 14

Review of Colorectal Cancer

19 19

Review of Lung Cancer

24 24

Review of Liver and Hepatobiliary Cancer

29 29

Review of Head and Neck Cancer

36 36

Hematologic Malignancies 2012

41 41

Age Distribution in All Male Cancer Number of Case

56 56

Age Distribution in All Female Cancer Number of Case

58 58

Breast Cancer Survival

61 61

Colorectal Cancer Survival

63 63

Lung Cancer Survival

66 66

Wattanosoth Hospital Conference

69 69

Cancer Registry Team


71 71

Wattanosoth Doctor Team

72 72



Message from CEO



A Buddhist proverb “*A-RO-KA-YA Pa-Ra-Ma-La-Pa*” or “*Health is Wealth*” is a best desire of every mankind. In consequence, people make every effort to fight with any unfavorable diseases and to prevent unforeseeable illnesses.

To relieve from such unpleasantness, especially the cancer ailment, many medical researches & development are conducted. The statistical data of patient’s demography, medical history, and treatment outcome are continuously gathered and considerably analyzed.

Wattanosoth Hospital, the “Home of Cancer Care”, significantly realizes an importance of those data; therefore, the Wattanosoth Cancer Registry Committee had continued our comprehensive Cancer registry program as exhibited by the Wattanosoth Cancer Registry 2012. The information and statistics contained in this annual report are seemed like a mirror that shows overview picture and guides the direction to remedy cancer. In addition, the hospital could also magnify its knowledge for developing future research and development projects.



I am proud to welcome all of you to the “*Wattanosoth Cancer Registry 2012*”. I am confident that all readers will find this report to be of great value because it delivers the variety sets of statistic and summary which can be applied in enhancing a better quality of patient care.

In this connection, I wish to extend my heartfelt gratitude and appreciation to the Cancer Registry Committee and to everyone who dedicated and sacrificed their time to deliver expertise, effort and contribution to this publication.

Chatree Duangnet, M.D. FAAP.

Chief Operating Officer - Medical Affairs, Bangkok Dusit Medical Services PCL.

Vice President, Bangkok Dusit Medical Services PCL.

Chief Executive Officer, Bangkok Hospital Medical Center

Message from Director

Wattanosoth Hospital dedicates to relieve our patients from their unpleasantness caused by cancer life-threatening. We; therefore, continually improve our services and develop standard of care in every dimension for enhancing the patient's quality of life.

Wattanosoth Cancer Registry is one of various dimensions that Wattanosoth Hospital has continuously developed. It gathered a comprehensive view of our cancer patients, related demographics, methods of care, and treatment outcomes over the past year. These statistics and information play an important role for our future Research & Development program. I would like to encourage you to review the useful content in this *“Wattanosoth Cancer Registry 2012”*.

Lastly, I take deep pride in the Cancer Registry Committee, including our physicians, nurses, medical personnel, and related team members perform, on behalf of Bangkok Hospital Medical Center, for their hard-working contribution to this publication.

“My warmest thanks and appreciation are specially extended to all of you”.

MG. Niwat Boonyuen

Major General Niwat Boonyuen M.D. FRCST., FICS.

Director, Wattanosoth Hospital
Bangkok Hospital Medical Center
Bangkok Hospitals Group





Wattanosoth Doctor Team




Chanawat Tesavibul
M.D.



Chatchai Koowattanapaisan
M.D.



Kanoknid Limvipaveanan
M.D.



Komgrit Tanisaro
M.D.



Kris Bhothisuwan
M.D.



Luksamee Chanvej
M.D.



Natchadol Kittiwarat
M.D.



Natthaphum Kanchanaporn
M.D.



Piyasak Thaharavanich
M.D.



Pornsri Kidchop
M.D.



Prasert Lertsanguansinchai
M.D.



Sakpisid Nawasiri
M.D.



Samart Ratchadara
M.D.



Sirikanya Chonsatientham
M.D.




Sirimana Ratanaprakarn
M.D.



Sirimon Piyavunno
M.D.




Sumitra Thongprasert
M.D.




Supakorn Rojananin
M.D.



Supara Leechasan
M.D.



Surachai Sitawarin
M.D.



Surachat Chakrapee-Sirisuk
M.D.




Surapol Issaragraisil
M.D.



Tanaphon Maipang
M.D.



Titima Purvaranukroh
M.D.



Viruch Charoeniam
M.D.

Cancer Registry 2012 : Abstract



The total of new cases diagnosed as a malignancy at Bangkok Hospital Medical Center is 1,854 cases (excluding the hematologic malignancy). There was a 10 percent decrease in the total number as compared to 2,066 cases in 2011. The increased number in 2011 was attributed to referrals from the National Cancer Institute (NCI) for investigations utilizing PET/CT, SPECT scan, bone scan and MUGA scan, only.

The sex ratio is 1:1. This age distribution has not changed since the year 2011. Patients who are between 50-69 y/o are the majority accounting for more than half of the total. The average age in male patients is 65-69 y/o which is slightly older than the female age of 50-54 y/o.

Top 5 malignancies are:

- | | |
|---------------------------------|-------------------------------------------|
| 1) Breast - 21.36 percent | 2) Colorectal - 11.92 percent |
| 3) Lung - 11.43 percent | 4) Liver and Hepatobiliary - 8.14 percent |
| 5) Head and Neck - 7.39 percent | |

The trend for the top 5 malignancies has changed over the past 6 years (2006-2011). Head and Neck cancer is 5 in 2012. For the past 6 years the top 5 have been: Breast, Colorectal, Lung and Liver and Prostate cancer. However, when compared to last year, the overall number of cases in Breast cancer decreased significantly by 41 percent, Colorectal cancer increased by 15 percent, Lung cancer decreased by 13 percent, Liver and Hepatobiliary increased by 10 percent and Head and Neck cancer increased by 10 percent.

The results of overall staging of patients who received treatment at Bangkok Hospital Medical Center (BMC) are: Stage I is 22 percent, Stage II is 23 percent, Stage III is 19 percent, and Stage IV is 23 percent. Unspecified stage (due to lack of pertinent information) is 8 percent. All results are similar to 2011 staging results.

Analysis of the primary treatments modalities indicates that surgery continues to be the majority (24 percent), followed by Radiation therapy (16 percent), Chemotherapy and Concurrent chemoradiation (4 percent). Intervention treatment remained at 3 percent.

Patients with a cancer diagnosis decide to receive treatment at Wattanosoth Cancer Hospital at 18 percent (14 percent in 2011) and 10 percent (7 percent in 2011) of cancer patients decide to have primary treatment in other hospitals. Patients who came from other hospitals for a second opinion at BMC significantly decreased to 35 percent (51 percent in 2011), however, those who decided to receive treatment at BMC increased to 55 percent (43 percent in 2011)


Patients who are still living after diagnosis or treatment in 2012 is 37 percent, patients alive without disease are 21 percent, and patients who have died with cancer as the cause are 2 percent. At this time no patients receiving treatment have been lost to follow-up.

Ratio of Thai to non-Thai patients is 3:2 in year 2012 equal to the year 2011. The top 5 rankings of non-Thai patients are: Myanmar, Bangladesh, United Arab Emirates, Oman and Qatar, respectively.

It is the third time BMC can follow the patients for 4 years and report the 4 years survival. We have shown and discussed the data of those survivors of top 3 cancers which are Breast, Colorectal And Lung in separated chapters.

WSH. ANNUAL CANCER REGISTRY 2012
DISTRIBUTION OF ALL CANCER BY AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	1	0.11	0	0.00	1	0.05
05 - 09	0	0.00	1	0.10	1	0.05
10 - 14	3	0.34	2	0.21	5	0.27
15 - 19	1	0.11	2	0.21	3	0.16
20 - 24	10	1.13	4	0.41	14	0.76
25 - 29	14	1.59	14	1.44	28	1.51
30 - 34	15	1.70	35	3.60	50	2.70
35 - 39	31	3.51	59	6.08	90	4.85
40 - 44	44	4.98	97	9.99	141	7.61
45 - 49	50	5.66	126	12.98	176	9.49
50 - 54	96	10.87	141	14.52	237	12.78
55 - 59	126	14.27	118	12.15	244	13.16
60 - 64	107	12.12	122	12.56	229	12.35
65 - 69	142	16.08	83	8.55	225	12.14
70 - 74	114	12.91	76	7.83	190	10.25
75 - 79	75	8.49	48	4.94	123	6.63
80 - 84	37	4.19	24	2.47	61	3.29
85 - 89	14	1.59	15	1.54	29	1.56
90 - 94	3	0.34	3	0.31	6	0.32
95 +	0	0.00	1	0.10	1	0.05
Total	883	100.00	971	100.00	1,854	100.00




OVERALL CANCER


THE TOP 10 LEADING SITE OF CANCER IN BMC

Code	Primary site	Male	Female	Total
C50	Breast (including in situ)	4	423	427
C18-C20	Colorectal	118	103	221
C33-C34	Lung	140	72	212
C22-C24	Liver & Hepatobiliary	115	36	151
C00-C14	Head & Neck	99	38	137
C61	Prostate	131	0	131
C53	Cervix	0	78	78
C73	Thyroid	18	53	71
C16	Stomach	28	27	55
C67	Bladder	34	3	37


TOP 10 CANCER FOR BOTH GENDER




TOP 10 CANCER IN MALE



TOP 10 CANCER IN FEMALE



PATIENT CATEGORY OF ALL CANCER IN BMC




Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)

Rx = Treatment

Here = Within Bangkok Hospital Medical Center


Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS (TREATMENT IN BMC)



Other = Previously diagnosed as Cancer from other Hospital but no documentation of diagnosis



STAGING (TREATMENT IN BMC)



Stage 0 = Carcinoma in situ

Non stage = In case of CA Brain

Unspecified stage = Incomplete staging due to insufficient patient information



TYPE OF TREATMENT

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	110	12.46	105	10.81	215	11.60
RT only	137	15.52	125	12.87	262	14.13
Brachytherapy	3	0.34	21	2.16	24	1.29
CT only	18	2.04	38	3.91	56	3.02
Targeted therapy	8	0.91	5	0.51	13	0.70
Immunotherapy	0	0.00	1	0.10	1	0.05
Hormonal therapy	6	0.68	6	0.62	12	0.65
Intervention	37	4.19	10	1.03	47	2.54
Nuclear medicine	4	0.45	13	1.34	17	0.92
Concurrent chemoradiation	30	3.40	26	2.68	56	3.02
Palliative care only	2	0.23	0	0.00	2	0.11
SUR.+RT	25	2.83	8	0.82	33	1.78
SUR.+CT	25	2.83	45	4.63	70	3.78
SUR.+T	1	0.11	0	0.00	1	0.05
SUR.+Im	6	0.68	1	0.10	7	0.38
SUR.+H	3	0.34	28	2.88	31	1.67
SUR.+I	0	0.00	1	0.10	1	0.05
SUR.+N	2	0.23	8	0.82	10	0.54
SUR.+Concurrent CT-RT	7	0.79	5	0.51	12	0.65
SUR.+Concurrent CT-RT+CT	2	0.23	1	0.10	3	0.16
RT+Brachytherapy	0	0.00	10	1.03	10	0.54
RT+Concurrent CT-RT	1	0.11	2	0.21	3	0.16
RT+T	5	0.57	2	0.21	7	0.38
RT+CT	8	0.91	12	1.24	20	1.08
RT+H	8	0.91	6	0.62	14	0.76
RT+I	1	0.11	0	0.00	1	0.05
CT+T	1	0.11	3	0.31	4	0.22
CT+H	0	0.00	1	0.10	1	0.05
I+T	3	0.34	1	0.10	4	0.22

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Concurrent CT-RT+Brachytherapy	0	0.00	8	0.82	8	0.43
Concurrent CT-RT+CT	2	0.23	1	0.10	3	0.16
SUR.+RT+CT	3	0.34	12	1.24	15	0.81
SUR.+RT+Brachytherapy	0	0.00	1	0.10	1	0.05
SUR.+RT+N	0	0.00	1	0.10	1	0.05
SUR.+RT+H	1	0.11	17	1.75	18	0.97
SUR.+RT+T	0	0.00	1	0.10	1	0.05
SUR.+CT+T	1	0.11	4	0.41	5	0.27
SUR.+CT+H	0	0.00	8	0.82	8	0.43
I+CT+T	1	0.11	0	0.00	1	0.05
SUR.+RT+CT+T	0	0.00	2	0.21	2	0.11
SUR.+RT+CT+H	0	0.00	11	1.13	11	0.59
SUR.+CT+T+H	0	0.00	1	0.10	1	0.05
SUR.+RT+CT+H+T	0	0.00	2	0.21	2	0.11
Investigation	107	12.12	96	9.89	203	10.95
Supportive	9	1.02	7	0.72	16	0.86
PET/CT	69	7.81	78	8.03	147	7.93
Bone scan	55	6.23	54	5.56	109	5.88
Follow up	0	0.00	3	0.31	3	0.16
2 nd Opinion	182	20.61	177	18.23	359	19.36
TBS scan	0	0.00	3	0.31	3	0.16
Total	883	100.00	971	100.00	1,854	100.00

SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy


H (Hormone) = Hormonal therapy

T = Targeted therapy


I = Intervention

Im = Immunotherapy

TYPE OF PRIMARY TREATMENT (ALL PATIENT)




PATIENT FOLLOW UP



2nd Opinion only = Intend not to continue diagnosis or treatment at BMC

REFERING HOSPITAL




BGH = Consult from Bangkok general hospital
 WSH only = WATTANOSOTH HOSPITAL
 BPH = BANGKOK PATTAYA HOSPITAL
 BNH = BNH HOSPITAL
 BKH = BANGKOK RATCHASIMA HOSPITAL
 BRH = BANGKOK RAYONG HOSPITAL
 BSH = BANGKOK SAMUI HOSPITAL
 BHN = BANGKOK HUAHIN HOSPITAL
 Paolo Group = Paolo memorial hospital Group

BGH only = Not consult from Bangkok general hospital
 SVH = SAMITVEJ SUKHUMVIT HOSPITAL
 BPK = BANGKOK PHUKET HOSPITAL
 SSH = SAMITVEJ SRIRACHA HOSPITAL
 SNH = SAMITVEJ SRINAKARIN HOSPITAL
 BHH = BANGKOK HATYAI HOSPITAL
 BCH = BANGKOK CHANTHABURI HOSPITAL
 PYT Group = Payathai hospital Group

PATIENT NATIONALITY

TOTAL NATIONALITY




Tumor site		Number
C50.0	Nipple	5
C50.1	Central portion of breast	1
C50.2	Upper-inner quadrant of breast	27
C50.3	Lower-inner quadrant of breast	14
C50.4	Upper-outer quadrant of breast	97
C50.5	Lower-outer quadrant of breast	27
C50.8	Overlapping lesion of breast	2
C50.9	Breast, NOS	254
Total		427

Pathology Report		Number
M8000/3	Malignant neoplasm	108
M8010/3	Carcinoma, NOS	1
M8140/3	Adenocarcinoma, NOS	3
M8480/3	Mucinous carcinoma	10
M8500/2	Ductal carcinoma in situ	31
M8500/3	Invasive ductal carcinoma	257
M8520/3	Lobular carcinoma	12
M8522/3	Invasive ductal and lobular carcinoma	2
M8523/3	Invasive duct mixed with other type of carcinoma	2
M9020/3	Malignant phyllodes tumor	1
Total		427


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	4	0.95	4	0.94
30 - 34	0	0.00	16	3.78	16	3.75
35 - 39	1	25.00	30	7.09	31	7.26
40 - 44	0	0.00	51	12.06	51	11.94
45 - 49	0	0.00	76	17.97	76	17.80
50 - 54	0	0.00	68	16.08	68	15.93
55 - 59	2	50.00	51	12.06	53	12.41
60 - 64	0	0.00	47	11.11	47	11.01
65 - 69	0	0.00	29	6.86	29	6.79
70 - 74	1	25.00	23	5.44	24	5.62
75 - 79	0	0.00	16	3.78	16	3.75
80 - 84	0	0.00	5	1.18	5	1.17
85 - 89	0	0.00	5	1.18	5	1.17
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	2	0.47	2	0.47
Total	4	100.00	423	100.00	427	100.00



PATIENT CATEGORY OF BREAST CANCER

Patient category	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Dx(Here)Rx(Other)	1	25.00	39	9.22	40	9.37
Dx(Here)Rx(Here)	0	0.00	96	22.70	96	22.48
Dx(Other)Rx(Here)	1	25.00	49	11.58	50	11.71
Dx(Other)Rx(Other)	2	50.00	146	34.52	148	34.66
Dx(Other)Rx(Other)Before	0	0.00	93	21.99	93	21.78
Total	4	100.00	423	100.00	427	100.00



Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)

Rx = Treatment

Here = Within Bangkok Hospital Medical Center


Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	0	0.00	26	10.92	26	10.88
Cytology	0	0.00	0	0.00	0	0.00
Histology	1	100.00	212	89.08	213	89.12
Imaging	0	0.00	0	0.00	0	0.00
Total	1	100.00	238	100.00	239	100.00

Other = Previously diagnosed as Breast cancer from other Hospital but no documentation of diagnosis

STAGING (TREATMENT IN BMC)




Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (IN BMC ONLY)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	0	0.00	40	16.81	40	16.74
RT only	0	0.00	61	25.63	61	25.52
CT only	0	0.00	16	6.72	16	6.69
Hormonal therapy	0	0.00	6	2.52	6	2.51
SUR.+RT	0	0.00	3	1.26	3	1.26
SUR.+CT	0	0.00	21	8.82	21	8.79
SUR.+H	0	0.00	27	11.34	27	11.30
RT+CT	1	100.00	5	2.11	6	2.51
RT+H	0	0.00	6	2.52	6	2.51
CT+T	0	0.00	1	0.42	1	0.42
SUR.+RT+CT	0	0.00	8	3.36	8	3.35
SUR.+RT+H	0	0.00	17	7.14	17	7.11
SUR.+CT+T	0	0.00	4	1.68	4	1.67
SUR.+CT+H	0	0.00	7	2.94	7	2.93
SUR.+RT+CT+T	0	0.00	2	0.84	2	0.84
SUR.+RT+CT+H	0	0.00	11	4.62	11	4.60
SUR.+CT+T+H	0	0.00	1	0.42	1	0.42
SUR.+RT+CT+H+T	0	0.00	2	0.84	2	0.84
Total	1	100.00	238	100.00	239	100.00

SUR. = Surgery, RT = External radiation therapy, CT = Chemotherapy, H (Hormone) = Hormonal therapy, T = Targeted therapy

FOLLOW UP STATUS (TREATMENT IN BMC)




Tumor site		Number
C18.0	Cecum colon	9
C18.2	Ascending colon	10
C18.3	Hepatic flexure of colon	7
C18.4	Transverse colon	9
C18.5	Splenic flexure of colon	4
C18.6	Descending colon	11
C18.7	Sigmoid colon	44
C18.9	Colon, NOS	28
C19.9	Rectosigmoid colon	14
C20.9	Rectum	85
Total		221

Pathology Report		Number
M8000/3	Malignant neoplasm	36
M8010/3	Carcinoma, NOS	1
M8070/3	Squamous cell carcinoma, NOS	1
M8140/3	Adenocarcinoma	160
M8240/3	Carcinoid tumor, NOS	1
M8246/3	Neuroendocrine carcinoma, NOS	1
M8480/3	Mucinous adenocarcinoma	11
M8481/3	Mucin producing adenocarcinoma	3
M8490/3	Adenocarcinoma signet ring cell type	7
Total		221


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	2	1.69	0	0.00	2	0.90
25 - 29	1	0.85	1	0.97	2	0.90
30 - 34	3	2.54	4	3.88	7	3.17
35 - 39	3	2.54	3	2.91	6	2.71
40 - 44	7	5.93	5	4.85	12	5.43
45 - 49	13	11.02	6	5.83	19	8.60
50 - 54	16	13.56	16	15.53	32	14.48
55 - 59	16	13.56	11	10.68	27	12.22
60 - 64	11	9.32	11	10.68	22	9.95
65 - 69	23	19.49	15	14.56	38	17.19
70 - 74	11	9.32	13	12.62	24	10.86
75 - 79	7	5.93	7	6.80	14	6.33
80 - 84	3	2.54	6	5.83	9	4.07
85 - 89	1	0.85	4	3.88	5	2.26
90 - 94	1	0.85	0	0.00	1	0.45
95 +	0	0.00	1	0.97	1	0.45
Total	118	100.00	103	100.00	221	100.00



PATIENT CATEGORY OF COLORECTAL CANCER

Patient category	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Dx(Here)Rx(Other)	17	14.41	6	5.83	23	10.41
Dx(Here)Rx(Here)	26	22.03	25	24.27	51	23.08
Dx(Other)Rx(Here)	15	12.71	17	16.50	32	14.48
Dx(Other)Rx(Other)	39	33.05	42	40.78	81	36.65
Dx(Other)Rx(Other)Before	21	17.80	13	12.62	34	15.38
Total	118	100.00	103	100.00	221	100.00



Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)

Rx = Treatment

Here = Within Bangkok Hospital Medical Center


Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	3	4.84	3	5.45	6	5.13
Cytology	0	0.00	0	0.00	0	0.00
Histology	59	95.16	52	94.55	111	94.87
Imaging	0	0.00	0	0.00	0	0.00
Total	62	100.00	55	100.00	117	100.00

Other = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis

STAGING (TREATMENT IN BMC)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (IN BMC ONLY)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	22	35.48	21	38.18	43	36.75
RT only	12	19.35	6	10.91	18	15.38
CT only	7	11.29	6	10.91	13	11.11
Intervention	0	0.00	1	1.82	1	0.85
Concurrent CT-RT	1	1.61	4	7.27	5	4.27
SUR.+RT	2	3.23	0	0.00	2	1.71
SUR.+CT	15	24.19	9	16.36	24	20.51
SUR.+I	0	0.00	1	1.82	1	0.85
SUR.+RT+CT	0	0.00	1	1.82	1	0.85
SUR.+CT+Concurrent CT-RT	1	1.61	0	0.00	1	0.85
SUR.+Concurrent CT-RT	1	1.61	3	5.45	4	3.42
RT+CT	0	0.00	2	3.64	2	1.71
CT+Concurrent CT-RT	1	1.61	1	1.82	2	1.71
Total	62	100.00	55	100.00	117	100.00


SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

FOLLOW UP STATUS (PATIENT TREATMENT IN BMC)




Tumor site		Number
C33.9	Trachea	1
C34.1	Upper lobe, lung	38
C34.2	Middle lobe, lung	8
C34.3	Lower lobe, lung	33
C34.9	Lung, NOS	132
Total		212

Pathology Report		Number
M8000/3	Malignant neoplasm	36
M8010/3	Carcinoma, NOS	7
M8012/3	Large cell carcinoma, NOS	1
M8020/3	Carcinoma undifferentiated, NOS	1
M8032/3	Spindle cell carcinoma	1
M8041/3	Small cell carcinoma, NOS	9
M8045/3	Small cell large cell carcinoma	3
M8046/3	Non small cell carcinoma	15
M8070/3	Squamous cell carcinoma, NOS	26
M8140/3	Adenocarcinoma, NOS	96
M8200/3	Adenoid cystic carcinoma	1
M8246/3	Neuroendocrine carcinoma, NOS	3
M8250/3	Bronchiolo-aveolar adenocarcinoma, NOS	6
M8251/3	Alveolar carcinoma	1
M8480/3	Mucinous adenocarcinoma	4
M8560/3	Adenosquamous carcinoma	2
Total		212


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	1	0.71	0	0.00	1	0.47
35 - 39	1	0.71	2	2.78	3	1.42
40 - 44	3	2.14	3	4.17	6	2.83
45 - 49	6	4.29	7	9.72	13	6.13
50 - 54	15	10.71	12	16.67	27	12.74
55 - 59	26	18.57	6	8.33	32	15.09
60 - 64	14	10.00	14	19.44	28	13.21
65 - 69	17	12.14	10	13.89	27	12.74
70 - 74	26	18.57	10	13.89	36	16.98
75 - 79	21	15.00	5	6.94	26	12.26
80 - 84	6	4.29	2	2.78	8	3.77
85 - 89	3	2.14	1	1.39	4	1.89
90 - 94	1	0.71	0	0.00	1	0.47
95 +	0	0.00	0	0.00	0	0.00
Total	140	100.00	72	100.00	212	100.00



PATIENT CATEGORY OF LUNG CANCER

Patient category	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Dx(Here)Rx(Other)	24	17.14	12	16.67	36	16.98
Dx(Here)Rx(Here)	28	20.00	11	15.28	39	18.40
Dx(Other)Rx(Here)	25	17.86	14	19.44	39	18.40
Dx(Other)Rx(Other)	49	35.00	26	36.11	75	35.38
Dx(Other)Rx(Other)Before	14	10.00	9	12.50	23	10.85
Total	140	100.00	72	100.00	212	100.00



Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)

Rx = Treatment

Here = Within Bangkok Hospital Medical Center


Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	4	5.97	3	8.82	7	6.93
Cytology	2	2.99	1	2.94	3	2.97
Histology	60	89.55	30	88.24	90	89.11
Imaging	1	1.49	0	0.00	1	0.99
Total	67	100.00	34	100.00	101	100.00

Other = Previously diagnosed as Lung cancer from other Hospital but no documentation of diagnosis

STAGING (TREATMENT IN BMC)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (IN BMC ONLY)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	10	14.93	2	5.88	12	11.88
RT only	34	50.75	17	50.00	51	50.50
CT only	3	4.48	3	8.82	6	5.94
Targeted therapy	3	4.48	4	11.76	7	6.93
Palliative care only	1	1.49	0	0.00	1	0.99
Concurrent CT-RT	3	4.48	1	2.94	4	3.96
SUR.+RT	1	1.49	0	0.00	1	0.99
SUR.+CT	1	1.49	0	0.00	1	0.99
SUR.+RT+CT	0	0.00	1	2.94	1	0.99
SUR.+RT+T	0	0.00	1	2.94	1	0.99
SUR.+Concurrent CT-RT	1	1.49	0	0.00	1	0.99
RT+CT	5	7.46	1	2.94	6	5.94
CT+T	1	1.49	2	5.88	3	2.97
RT+T	4	5.97	2	5.88	6	5.94
Total	67	100.00	34	100.00	101	100.00


SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy


T = Targeted therapy

FOLLOW UP STATUS (TREATMENT IN BMC)



Tumor site		Number
C22.0	Liver	111
C22.1	Intrahepatic bile duct	30
C23.9	Gall bladder	4
C24.0	Extrahepatic bile duct	2
C24.1	Ampullar of vater	4
Total		151


Pathology Report		Number
M8000/3	Malignant neoplasm	90
M8140/3	Adenocarcinoma, NOS	7
M8144/3	Adenocarcinoma, intestinal type	1
M8160/3	Cholangiocarcinoma	14
M8162/3	Klatskin tumor	1
M8170/3	Hepatocellular carcinoma, NOS	36
M8174/3	Hepatocellular CA, clear cell type	1
M8260/3	Papillary adenocarcinoma	1
Total		151





Malignant neoplasm = Dx For Cancer but unknow special type

AGE AND GENDER

Hepatocellular Carcinoma only



Hepatocellular Carcinoma only





Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)

Rx = Treatment



Here = Within Bangkok Hospital Medical Center

Other = Outside Bangkok Hospital Medical Center

Hepatocellular Carcinoma only



Hepatocellular Carcinoma only



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (IN BMC ONLY)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	7	11.48	2	11.11	9	11.39
RT only	5	8.20	2	11.11	7	8.86
CT only	2	3.28	2	11.11	4	5.06
Targeted therapy	2	3.28	1	5.56	3	3.80
Intervention	37	60.66	9	50.00	46	58.23
Palliative care only	1	1.64	0	0.00	1	1.27
SUR.+CT	1	1.64	0	0.00	1	1.27
SUR.+T	1	1.64	0	0.00	1	1.27
T+I	3	4.92	1	5.56	4	5.06
RT+CT	0	0.00	1	5.56	1	1.27
RT+I	1	1.64	0	0.00	1	1.27
CT+T+I	1	1.64	0	0.00	1	1.27
Total	61	100.00	18	100.00	79	100.00

SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

I = Intervention

TYPE OF TREATMENT IN HEPATOCELLULAR CARCINOMA (IN BMC ONLY)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	4	7.84	2	14.29	6	9.23
RT only	2	3.92	2	14.29	4	6.15
Targeted therapy	2	3.92	1	7.14	3	4.62
Intervention	37	72.55	8	57.14	45	69.23
SUR.+T	1	1.96	0	0.00	1	1.54
T+I	3	5.88	1	7.14	4	6.15
RT+I	1	1.96	0	0.00	1	1.54
CT+T+I	1	1.96	0	0.00	1	1.54
Total	51	100.00	14	100.00	65	100.00



SUR. = Surgery

RT = External radiation therapy

I = Intervention

T = Targeted therapy

Hepatocellular Carcinoma only




Tumor site		Number
C00.1	Lower lip	1
C01.9	Base of tongue	8
C02.9	Tongue	16
C03.1	Lower alveolus	1
C03.9	Gum	1
C04.9	Floor of mouth	4
C05.0	Hard palate	1
C05.1	Soft palate	1
C05.9	Palate	2
C06.0	Buccal mucosa	9
C07.9	Parotid gland	1
C08.0	Submandibular gland	2
C08.1	Sublingual gland	1
C09.1	Tonsillar pillar	1
C09.9	Tonsil	9
C10.9	Oropharynx	1
C11.9	Nasopharynx	70
C12.9	Pyriform sinus	3
C13.0	Postcricoid region	1
C13.9	Hypopharynx	2
C14.0	Pharynx	2
Total		137

Pathology Report		Number
M8000/3	Malignant neoplasm	22
M8010/3	Carcinoma, NOS	2
M8020/3	Carcinoma undifferentiated, NOS	24
M8021/3	Carcinoma, anaplastic, NOS	1
M8051/3	Verrucous carcinoma, NOS	1
M8070/3	Squamous cell carcinoma, NOS	69
M8071/3	Squamous cell carcinoma, keratinizing, NOS	2
M8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	14
M8200/3	Adenoid cystic carcinoma	2
Total		137


AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	1	1.01	1	2.63	2	1.46
20 - 24	2	2.02	1	2.63	3	2.19
25 - 29	2	2.02	1	2.63	3	2.19
30 - 34	3	3.03	2	5.26	5	3.65
35 - 39	6	6.06	2	5.26	8	5.84
40 - 44	9	9.09	4	10.53	13	9.49
45 - 49	12	12.12	3	7.89	15	10.95
50 - 54	13	13.13	7	18.42	20	14.60
55 - 59	16	16.16	5	13.16	21	15.33
60 - 64	16	16.16	4	10.53	20	14.60
65 - 69	10	10.10	2	5.26	12	8.76
70 - 74	4	4.04	4	10.53	8	5.84
75 - 79	5	5.05	1	2.63	6	4.38
80 - 84	0	0.00	0	0.00	0	0.00
85 - 89	0	0.00	1	2.63	1	0.73
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	99	100.00	38	100.00	137	100.00



PATIENT CATEGORY OF HEAD AND NECK CANCER

Patient category	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Dx(Here)Rx(Other)	8	8.08	1	2.63	9	6.57
Dx(Here)Rx(Here)	10	10.10	5	13.16	15	10.95
Dx(Other)Rx(Here)	33	33.33	12	31.58	45	32.85
Dx(Other)Rx(Other)	37	37.37	8	21.05	45	32.85
Dx(Other)Rx(Other)Before	11	11.11	12	31.58	23	16.79
Total	99	100.00	38	100.00	137	100.00



Dx = Diagnosis for Cancer (Dx by Pathology, Cytology or Imaging)

Rx = Treatment

Here = Within Bangkok Hospital Medical Center


Other = Outside Bangkok Hospital Medical Center

METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	2	3.70	1	3.45	3	3.61
Cytology	0	0.00	0	0.00	0	0.00
Histology	52	96.30	28	96.55	80	96.39
Imaging	0	0.00	0	0.00	0	0.00
Total	54	100.00	29	100.00	83	100.00

Other = Previously diagnosed as Head and Neck cancer from other Hospital but no document of Pathology

STAGING (TREATMENT IN BMC)



Unspecified stage = Incomplete staging due to insufficient patient information

TYPE OF TREATMENT (IN BMC ONLY)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	7	12.96	4	13.79	11	13.25
RT+Brachytherapy	23	42.59	13	44.83	36	43.37
CT only	0	0.00	1	3.45	1	1.20
Concurrent CT-RT	17	31.48	7	24.14	24	28.92
SUR.+RT	2	3.70	2	6.90	4	4.82
SUR.+RT+CT	1	1.85	0	0.00	1	1.20
SUR.+Concurrent CT-RT	1	1.85	1	3.45	2	2.41
RT+CT	0	0.00	1	3.45	1	1.20
RT+T	1	1.85	0	0.00	1	1.20
RT+Concurrent CT-RT	1	1.85	0	0.00	1	1.20
CT+Concurrent CT-RT	1	1.85	0	0.00	1	1.20
Total	54	100.00	29	100.00	83	100.00


SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy


FOLLOW UP STATUS (TREATMENT IN BMC)



HEMATOLOGIC MALIGNANCIES 2012


DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES


Disease	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Hodgkin's disease	17	17.53	7	10.61	24	14.72
Follicular non-Hodgkin's lymphoma	5	5.15	3	4.55	8	4.91
Diffuse non-Hodgkin's lymphoma	30	30.93	26	39.39	56	34.36
Peripheral and cutaneous T-cell lymphoma	4	4.12	3	4.55	7	4.29
Other and unspecified type of non-Hodgkin's lymphoma	9	9.28	4	6.06	13	7.98
Multiple myeloma and malignant plasma cell neoplasm	5	5.15	6	9.09	11	6.75
Lymphoid leukemia	8	8.25	1	1.52	9	5.52
Myeloid leukemia	19	19.59	16	24.24	35	21.47
Total	97	100.00	66	100.00	163	100.00



DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES BY AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	2	2.06	1	1.52	3	1.84
05 - 09	5	5.15	0	0.00	5	3.07
10 - 14	1	1.03	1	1.52	2	1.23
15 - 19	5	5.15	1	1.52	6	3.68
20 - 24	5	5.15	4	6.06	9	5.52
25 - 29	5	5.15	4	6.06	9	5.52
30 - 34	4	4.12	4	6.06	8	4.91
35 - 39	5	5.15	2	3.03	7	4.29
40 - 44	8	8.25	6	9.09	14	8.59
45 - 49	4	4.12	2	3.03	6	3.68
50 - 54	11	11.34	7	10.61	18	11.04
55 - 59	10	10.31	12	18.18	22	13.50
60 - 64	7	7.22	8	12.12	15	9.20
65 - 69	9	9.28	8	12.12	17	10.43
70 - 74	7	7.22	2	3.03	9	5.52
75 - 79	4	4.12	1	1.52	5	3.07
80 - 84	2	2.06	1	1.52	3	1.84
85 - 89	2	2.06	1	1.52	3	1.84
90 - 94	0	0.00	1	1.52	1	0.61
95 +	1	1.03	0	0.00	1	0.61
Total	97	100.00	66	100.00	163	100.00





Dx = Diagnosis for cancer


Rx = Treatment


Here = Within Bangkok Hospital Medical Center

Other = Outside Bangkok Hospital Medical Center

PATIENT NATIONALITY


Patient nationality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Thai	39	40.21	35	53.03	74	45.40
Foreign	58	59.79	31	46.97	89	54.60
Total	97	100.00	66	100.00	163	100.00






LYMPHOMA AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	3	4.62	0	0.00	3	2.78
10 - 14	0	0.00	1	2.33	1	0.93
15 - 19	4	6.15	1	2.33	5	4.63
20 - 24	4	6.15	3	6.98	7	6.48
25 - 29	3	4.62	1	2.33	4	3.70
30 - 34	3	4.62	3	6.98	6	5.56
35 - 39	3	4.62	0	0.00	3	2.78
40 - 44	5	7.69	4	9.30	9	8.33
45 - 49	3	4.62	2	4.65	5	4.63
50 - 54	7	10.77	3	6.98	10	9.26
55 - 59	7	10.77	10	23.26	17	15.74
60 - 64	6	9.23	5	11.63	11	10.19
65 - 69	8	12.31	6	13.95	14	12.96
70 - 74	5	7.69	1	2.33	6	5.56
75 - 79	3	4.62	1	2.33	4	3.70
80 - 84	0	0.00	1	2.33	1	0.93
85 - 89	1	1.54	0	0.00	1	0.93
90 - 94	0	0.00	1	2.33	1	0.93
95 +	0	0.00	0	0.00	0	0.00
Total	65	100.00	43	100.00	108	100.00




Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	3	4.62	1	2.33	4	3.70
≥ 15 yr.	62	95.38	42	97.67	104	96.30
Total	65	100.00	43	100.00	108	100.00



METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Conclude method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology only	17	65.38	11	73.33	28	68.29
Histopathology+Flow cytometry+Chromosome	1	3.85	1	6.67	2	4.88
Histopathology+Flow cytometry	6	23.08	1	6.67	7	17.07
Histopathology+Immunohistochemistry	1	3.85	1	6.67	2	4.88
Histopathology+Flow cytometry+Immunohistochemistry	1	3.85	1	6.67	2	4.88
Total	26	100.00	15	100.00	41	100.00


STAGING (TREATMENT IN BMC)



Unspecified stage = Incomplete staging due to insufficient patient information


TYPE OF TREATMENT (TREATMENT IN BMC)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery only	2	7.69	3	20.00	5	12.20
Radiationtherapy only	7	26.92	2	13.33	9	21.95
Chemotherapy	14	53.85	9	60.00	23	56.10
Radiationtherapy+Chemotherapy	2	7.69	1	6.67	3	7.32
Chemotherapy+Bone marrow transplantatin	1	3.85	0	0.00	1	2.44
Total	26	100.00	15	100.00	41	100.00




MULTIPLE MYELOMA AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	0	0.00	0	0.00	0	0.00
35 - 39	0	0.00	0	0.00	0	0.00
40 - 44	0	0.00	0	0.00	0	0.00
45 - 49	0	0.00	0	0.00	0	0.00
50 - 54	2	33.33	1	25.00	3	30.00
55 - 59	1	16.67	0	0.00	1	10.00
60 - 64	0	0.00	2	50.00	2	20.00
65 - 69	0	0.00	1	25.00	1	10.00
70 - 74	1	16.67	0	0.00	1	10.00
75 - 79	1	16.67	0	0.00	1	10.00
80 - 84	1	16.67	0	0.00	1	10.00
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
Total	6	100.00	4	100.00	10	100.00



Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	0	0.00	0	0.00	0	0.00
≥ 15 yr.	5	100.00	5	100.00	10	100.00
Total	5	100.00	5	100.00	10	100.00




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Conclude method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology only	2	50.00	3	100.00	5	71.43
Histopathology+Flow cytometry	2	50.00	0	0.00	2	28.57
Total	4	100.00	3	100.00	7	100.00


TYPE OF TREATMENT (TREATMENT IN BMC)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiationtherapy only	1	25.00	1	33.33	2	28.57
Chemotherapy	1	25.00	0	0.00	1	14.29
Targetedtherapy	0	0.00	1	33.33	1	14.29
Bone marrow transplantatin	0	0.00	1	33.33	1	14.29
Radiationtherapy+Chemotherapy	1	25.00	0	0.00	1	14.29
Chemotherapy+Bone marrow transplantatin	1	25.00	0	0.00	1	14.29
Total	4	100.00	3	100.00	7	100.00




LEUKEMIA
AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	2	7.41	1	5.56	3	6.67
05 - 09	2	7.41	0	0.00	2	4.44
10 - 14	1	3.70	0	0.00	1	2.22
15 - 19	1	3.70	0	0.00	1	2.22
20 - 24	1	3.70	1	5.56	2	4.44
25 - 29	2	7.41	3	16.67	5	11.11
30 - 34	1	3.70	1	5.56	2	4.44
35 - 39	2	7.41	2	11.11	4	8.89
40 - 44	3	11.11	2	11.11	5	11.11
45 - 49	1	3.70	0	0.00	1	2.22
50 - 54	3	11.11	2	11.11	5	11.11
55 - 59	2	7.41	2	11.11	4	8.89
60 - 64	1	3.70	1	5.56	2	4.44
65 - 69	1	3.70	1	5.56	2	4.44
70 - 74	1	3.70	1	5.56	2	4.44
75 - 79	0	0.00	0	0.00	0	0.00
80 - 84	1	3.70	0	0.00	1	2.22
85 - 89	1	3.70	1	5.56	2	4.44
90 - 94	0	0.00	0	0.00	0	0.00
95 +	1	3.70	0	0.00	1	2.22
Total	27	100.00	18	100.00	45	100.00



Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	5	7.41	1	5.56	6	13.33
≥ 15 yr.	22	81.48	17	94.44	39	86.67
Total	27	88.89	18	100.00	45	100.00




METHOD OF DIAGNOSIS (TREATMENT IN BMC)

Conclude method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology only	3	33.33	1	11.11	4	22.22
Histopathology+Flow cytometry+Chromosome	2	22.22	2	22.22	4	22.22
Histopathology+Flow cytometry	4	44.44	6	66.67	10	55.56
Total	9	100.00	9	100.00	18	100.00

TYPE OF TREATMENT (TREATMENT IN BMC)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemotherapy	5	55.56	5	55.56	10	55.56
Targeted therapy only	1	11.11	2	22.22	3	16.67
Chemotherapy+Radiationtherapy	1	11.11	0	0.00	1	5.56
Chemotherapy+Targeted therapy	1	11.11	0	0.00	1	5.56
Chemotherapy+Bone marrow transplantation	1	11.11	2	22.22	3	16.67
Total	9	100.00	9	100.00	18	100.00



AGE DISTRIBUTION IN ALL MALE CANCER NUMBER OF CASE

Code	Primary site	00	05	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	90	95	Total	%
		04	09	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84	89	94	+		
C00	Lip	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0.11
C01-C02	Tongue	0	0	0	0	0	0	0	0	1	2	2	4	4	3	1	0	0	0	0	0	17	1.93
C03	Gum	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	2	0.23
C04	Floor of mouth	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	0	0	0	0	0	4	0.45
C05	Palate	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2	0.23
C06	Other part of mouth	0	0	0	0	0	0	0	1	0	1	2	1	1	0	0	0	0	0	0	0	6	0.68
C07	Parotid gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C08	Salivary gland	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0.11
C09	Tonsil	0	0	0	0	0	1	0	0	0	0	0	1	2	2	0	0	0	0	0	0	6	0.68
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.11
C11-C14	Head & Neck	0	0	0	1	2	1	3	4	6	9	9	8	6	4	2	4	0	0	0	0	59	6.68
C15	Esophagus	0	0	0	0	0	0	0	0	0	1	3	5	3	2	1	2	1	1	1	0	20	2.27
C16	Stomach	0	0	0	0	0	0	0	0	5	1	1	5	3	1	3	3	4	2	0	0	28	3.17
C17	Small intestine	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.11
C18-C20	Colon & Rectum	0	0	0	0	2	1	3	3	7	13	16	16	11	23	11	7	3	1	1	0	118	13.36
C21	Anus	0	0	0	0	0	0	0	1	0	1	0	1	0	1	0	0	0	0	0	0	4	0.45
C22-C24	Liver & Hepatobiliary	0	0	0	0	0	0	1	4	8	7	13	20	16	22	11	9	4	0	0	0	115	13.02
C25	Pancreas	0	0	0	0	0	0	0	0	0	1	2	5	4	4	1	0	1	1	0	0	19	2.15
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.11
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C32	Larynx	0	0	0	0	0	0	0	0	1	2	3	3	4	9	4	3	0	0	0	0	29	3.28
C33-C34	Lung	0	0	0	0	0	0	1	1	3	6	15	26	14	17	26	21	6	3	1	0	140	15.86
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C38	Mediastinum	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.23
C40-C41	Bone	0	0	1	0	2	0	0	0	3	0	1	0	0	1	0	0	1	0	0	0	9	1.02
C43-C44	Skin	0	0	0	0	0	0	0	0	0	0	2	4	6	3	6	2	1	0	0	0	24	2.72
C48	Retroperitoneum	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0.11

Code	Primary site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C49	Connective tissue	0	0	0	0	0	2	1	1	0	1	1	1	0	3	2	0	0	2	0	0	14	1.59
C50	Breast	0	0	0	0	0	0	0	1	0	0	0	2	0	0	1	0	0	0	0	0	4	0.45
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C52	Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C53	Cervix	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C54	Corpus uteri	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C55	Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C56	Ovary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	3	0.34
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	10	8	23	33	30	16	9	2	0	0	131	14.84
C62	Testis	0	0	0	0	0	2	0	1	2	0	0	0	0	0	0	0	0	0	0	0	5	0.57
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	2	0.23
C64-C65	Urinary tract	0	0	0	0	0	1	1	4	1	3	4	4	1	2	2	4	1	1	0	0	29	3.28
C66	Ureter	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	2	0.23
C67	Bladder	1	0	0	0	0	0	1	0	0	0	5	3	0	7	9	2	5	1	0	0	34	3.85
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye & Adnexa	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0.23
C70-C71	Brain	0	0	0	0	0	2	3	5	1	1	0	3	1	1	1	0	1	0	0	0	19	2.15
C72	Spinal cord & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	1	0	2	1	1	2	3	0	2	2	2	1	1	0	0	0	0	0	18	2.04
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.11
C75	Other & endocrine gland	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.23
C76	Other & ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C79	Unknown primary site	0	0	0	0	0	0	0	0	0	0	1	0	2	2	1	1	0	0	0	0	7	0.79
D05	Ductal carcinoma in situ of breast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
All ICD Group		1	0	3	1	10	14	15	31	44	50	96	126	107	142	114	75	37	14	3	0	883	100.00

AGE DISTRIBUTION IN ALL FEMALE CANCER NUMBER OF CASE

Code	Primary site	00	05	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	90	95	Total	%
		04	09	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84	89	94	+		
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C01-C02	Tongue	0	0	0	0	0	1	1	0	1	1	0	0	0	1	1	0	0	0	0	0	7	0.72
C03	Gum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C04	Floor of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C05	Palate	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	2	0.21
C06	Other part of mouth	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	3	0.31
C07	Parotid gland	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0.10
C08	Salivary gland	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	2	0.21
C09	Tonsil	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	4	0.41
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C11-C14	Head & Neck	0	0	0	1	1	0	1	1	0	1	5	3	2	1	1	1	0	1	0	0	19	1.96
C15	Esophagus	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	1	0	0	0	4	0.41
C16	Stomach	0	0	0	0	0	0	0	0	1	2	4	8	3	3	3	1	1	1	0	0	27	2.78
C17	Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.10
C18-C20	Colon & Rectum	0	0	0	0	0	1	4	3	5	6	16	11	11	15	13	7	6	4	0	1	103	10.61
C21	Anus	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	2	0.21
C22-C24	Liver & Hepatobiliary	0	0	0	0	0	0	0	0	2	5	2	7	7	4	5	1	2	1	0	0	36	3.71
C25	Pancreas	0	0	0	0	0	0	0	1	0	0	1	3	0	1	2	1	0	0	0	0	9	0.93
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C30	Nasal cavity	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0.10
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	0	4	0.41
C32	Larynx	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	3	0.31
C33-C34	Lung	0	0	0	0	0	0	0	2	3	7	12	6	14	10	10	5	2	1	0	0	72	7.42
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C38	Mediastinum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C40-C41	Bone	0	0	0	1	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	4	0.41
C43-C44	Skin	0	0	0	0	0	0	1	0	1	0	0	1	1	2	0	1	1	0	0	0	8	0.82
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0.10

Code	Primary site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	95+	Total	%
C49	Connective tissue	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	1	2	0	0	6	0.62
C50	Breast	0	0	0	0	0	4	15	27	47	70	63	46	42	29	22	15	5	5	2	0	392	40.37
C51	Vulva	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	3	0.31
C52	Vagina	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	2	0.21
C53	Cervix	0	0	0	0	0	0	3	4	13	8	11	12	12	5	4	5	1	0	0	0	78	8.03
C54	Corpus uteri	0	0	0	0	0	0	0	1	1	1	6	3	9	7	3	2	1	0	0	0	34	3.50
C55	Uterus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C56	Ovary	0	0	0	1	0	0	1	0	4	6	6	5	2	0	2	0	1	0	1	0	29	2.99
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C62	Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	1	0	0	0	1	0	0	0	1	0	0	1	0	1	1	0	0	0	0	6	0.62
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0.10
C67	Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	3	0.31
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0.10
C69	Eye & Adnexa	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.10
C70-C71	Brain	0	0	1	0	0	1	0	1	1	2	0	3	1	0	0	1	0	0	0	0	11	1.13
C72	Spinal cord & CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	0	0	2	5	8	10	8	6	4	2	2	1	3	2	0	0	0	0	53	5.46
C74	Adrenal gland	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0.10
C75	Other & endocrine gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C76	Other & ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C79	Unknown primary site	0	0	0	0	0	0	0	2	1	1	0	0	2	0	0	0	0	0	0	0	6	0.62
D05	Ductal carcinoma in situ of breast	0	0	0	0	0	0	1	3	4	6	5	5	5	0	1	1	0	0	0	0	31	3.19
All ICD Group		0	1	1	3	4	14	35	59	97	126	141	118	122	83	76	48	24	15	3	1	971	100.00

This report on cancer survival is based on an analysis of data of top 3 common cancers (i.e., breast, colorectal and lung cancer) in Wattanosoth Cancer Hospital (WSH). The data has been collected by the hospital cancer registry. The cancer patients were diagnosed during a 12 month period from January 1 to December 31, 2008. All of them received treatment at WSH and were prospectively followed-up up to December 31, 2012 (4 year follow-up period).

Survival rates were estimated by Kaplan-Meier method. The survival rates of subgroups of cancer patients categorized by age (aged ≤ 50 and > 50 years old), sex (male and female) and stage of cancer at diagnosis (stage 1-4) were analyzed for comparison.

As this report is hospital registry-based cancer survival analysis, the study may have limitations related to endpoint data and sample size. The observed survival rates are estimated by method which cumulative probability of survival is calculated at consecutive one-month intervals after diagnosis. The information used included death from the cancer and other causes; lost to follow-up before observation period ended; and follow-up ends due to observation period ended. Therefore survival estimated may be biased if the proportion of lost to follow-up or other causes of death is high. Survival rate estimated from small numbers of cases can provide misleading results and may have wide confidence intervals. In addition to compare survival rate between different groups, test for statistical significant may be misleading.

125 cases were diagnosed breast cancer during January 1 to December 31, 2008. At the time of diagnosis, 48 (38.4%) of them were at stage 1, 39 (31.2%) at stage 2, 21 (16.8%) at stage 3, and 11 (8.8%) at stage 4. Their average age was 53.1 years old (SD \pm 12.1). 54 (43.2%) of them aged \leq 50 years old and 71 (56.8%) aged $>$ 50 years old.

The median follow-up period of these breast cancer patients was 49 months (25th - 75th percentile: 20 - 54 months). During the 4 year follow-up period, 4 of them were dead and 1 were lost to follow-up.

The overall observed survival rate of the breast cancer patients at 4 year follow-up period was 95.5% (95% CI: 88.4 - 98.3) (Fig. 1). The survival seems to have no difference between the age group of $>$ 50 and \leq 50 years old, of which the survival rate was 95.9% (95% CI: 84.6 - 99.0), and 95.1% (95% CI: 81.6 - 98.7) respectively (Fig. 2).

The observed survival of the early stage breast cancers, i.e., stage 1 and 2 was 100.0% and 100.0% respectively, while the survival of the late stages, i.e., stage 3 and 4 was 83.9% (95% CI: 49.4 to 95.7) and 66.7% (95% CI: 5.4 to 94.5) respectively (Fig. 3). The survival rate tends to be lower in the late stage breast cancers.




Figure 1. Overall observed survival rate of the breast cancer patients in WSH during 4 year follow-up period




Figure 2. Observed survival rate of the breast cancer patients in WSH during 4 year follow-up period by age group of ≤ 50 and > 50 years old




Figure 3. Observed survival rate of the breast cancer patients in WSH during 4 year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

58 cases were diagnosed colorectal cancer during January 1 to December 31, 2008. At the time of diagnosis, 6 (10.3%) of them were at stage 1, 10 (17.2%) at stage 2, 24 (41.4%) at stage 3, and 13 (22.4%) at stage 4. Their average age was 62.4 years old (SD ± 13.2). 11 (19.0%) of them aged ≤ 50 years old and 47 (81.0%) aged > 50 years old. Among of them, there were 41 (70.7%) males and 17 (29.3%) females.

The median follow-up period of these colorectal cancer patients was 20 months (25th - 75th percentile: 5 - 45 months). During the 4 year follow-up period, 9 of them were dead and 4 were lost to follow-up.

The overall observed survival rate of the colorectal cancer patients at 4 year follow-up period was 85.2% (95% CI: 71.1 - 92.8) (Fig. 1). The survival among the male patients was 68.3% (95% CI: 27.9 - 89.2) and female was 84.6% (95% CI: 51.2 - 95.9) (Fig. 2). The male patients seem to have lower observed survival rate. The survival seems to have no difference between the age group of > 50 and ≤ 50 years old, of which the survival rate was 70.1% (95% CI: 35.0 - 88.7) and 90.0% (95% CI: 47.3 - 98.5) respectively (Fig. 3).

The observed survival of early stage colorectal cancers, i.e., stage 1 and 2 was 100.0% and 83.3% (95% CI: 27.3 - 97.5) respectively, while the survival of the late stages, i.e., stage 3 and 4 was 87.1% (95% CI: 65.0 - 95.6) and 33.7% (95% CI: 1.6 - 75.3) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced. Especially in the stage 4, the survival was substantially decreased.




Figure 1. Overall observed survival rate of the colorectal cancer patients in WSH during 4 year follow-up period




Figure 2. Observed survival rate of the colorectal cancer patients in WSH during 4 year follow-up period by gender (male and female)




Figure 3. Observed survival rate of the colorectal cancer patients in WSH during 4 year follow-up period by age group of ≤ 50 and > 50 years old




Figure 4. Observed survival rate of the colorectal cancer patients in WSH during 4 year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

74 cases were diagnosed lung cancer during January 1 to December 31, 2008. At the time of diagnosis, 13 (17.6%) of them were at stage 1, 1 (1.3%) at stage 2, 9 (12.2%) at stage 3, and 47 (63.5%) at stage 4. Their average age was 61.6 years old (SD \pm 12.1). 12 (16.2%) of them aged \leq 50 years old and 62 (83.8%) aged $>$ 50 years old. Among of them, there were 48 (64.9%) males and 26 (35.1%) females.

The median follow-up period of these lung cancer patients was 9 months (25th - 75th percentile: 3 - 27). During the 4 year follow-up period, 26 of them were dead and 1 were lost to follow-up.

The observed survival rate of the lung cancer patients at 4 year follow-up period was 45.7% (95% CI: 29.1 - 60.8) (Fig. 1). The survival seems to have no difference between male and female patients, of which the survival rate was 33.5% (95% CI: 13.4 - 55.1) and 60.3% (95% CI: 34.4 - 78.7) respectively (Fig. 2). The survival of patients aged $>$ 50 and \leq 50 years old was 46.9% (95% CI: 28.8 - 63.1) and 48.6% (95% CI: 16.0 - 75.3) respectively (Fig. 3). The patients aged $>$ 50 years old seem to have lower observed survival rate.

The observed survival rate of early stage lung cancers, i.e., stage 1 and 2 was 100.0% and 100.0% respectively while the survival of late stages, i.e., stage 3 and 4 was 44.4% (95% CI: 10.4 - 74.8) and 16.5% (95% CI: 3.1 - 38.4) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced.




Figure 1. Overall observed survival rate of the lung cancer patients in WSH during 4 year follow-up period




Figure 2. Observed survival rate of the lung cancer patients in WSH during 4 year follow-up period by gender (male and female)




Figure 3. Observed survival rate of the lung cancer patients in WSH during 4 year follow-up period by age group of ≤ 50 and > 50 years old




Figure 4. Observed survival rate of the lung cancer patients in WSH during 4 year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

3rd Best Practice for Cancer Care

Prof. Richard Champlin, M.D. MDAAC.

Chair, Department of Stem Cell Transplantation and Cellular Therapy,

The University of Texas MD Anderson Cancer Center, Houston USA. Joined with “3rd Best Practice for Cancer Care” gave speech on “Critical Role of Nursing Care in Improving Patient Outcomes” on 21-22 February 2013 at 7R conference Room, Bangkok Hospital.



3rd Bangkok Annual Colorectal Cancer Conference



Asso. Prof. Mehnaz A Shafi, M.D.

Associate Professor, Gastroenterology, Hepatology and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Joined with “3rd Bangkok Annual Colorectal Cancer Conference” gave speech on “Screening tools for Colorectal Cancer, Genetics and Family History in Colorectal Cancer” on 14 March 2013 at 7R Conference Room, Bangkok Hospital.

3rd Bangkok Annual Colorectal Cancer Conference

Prof. Chusilp Charnsangavej, M.D. FSIR

Professor, Department of Diagnostic Radiology

The University of Texas MD Anderson Cancer Center, Houston, TX. Joined with “3rd Bangkok Annual Colorectal Cancer Conference” gave speech on “Advance in Colorectal cancer imaging” on 14 March 2013 at 7R Conference Room, Bangkok Hospital.




Practical Radiation Oncology in Head & Neck Cancer



Prof. David I Rosenthal, M.D. F.A.C.R.


Head and Neck Radiation Oncology, Section Chief. The University of Texas MD Anderson Cancer Center. Joined with “Practical Radiation Oncology in Head & Neck Cancer” gave speech on “Current Radiation Oncology in H&N” and “Treatment of Locally Advanced Oropharyngeal SCCA” on 28 March 2013 at 7R Conference Room, Bangkok Hospital.



Komgrit Tanisaro
M.D.



Natthaphum Khanchanaporn
M.D.



Surachai Sitawarin
M.D.



Saengduan Chindavijak
M.D.



Waraphorn Chomphu
Tumor Registered-Officer (WSH)



Pichet Pariyarungsi
Senior Business Intelligence Manager

No.	NAME	SPECIALTY	REMARK
1.	Surapol Issaragraisil, M.D.	Hematologist	Part-time
2.	Supara Leechasan, M.D.	Hematologist	Full-time
3.	Sirimon Piyavunno, M.D.	Hematologist	Full-time
4.	Kannadit Proyongratana, M.D.	Hematologist	Part-time
5.	Nopadol Siritanarattanakul, M.D.	Hematologist	Part-time
6.	Bundarika Suwanawiboon, M.D.	Hematologist	Part-time
7.	Wirote Lausoontornsiri, M.D.	Hematologist	Part-time
8.	Theera Ruchutrakool, M.D.	Hematologist	Part-time
9.	Nuchanan Areethamsirikul, M.D.	Hematologist	Part-time
10.	Chajchawan Nakhakes, M.D.	Hematologist	Part-time
11.	Photsawee Khemaphiphat, M.D.	Hematologist	Full-time
12.	Manop Pithukpakorn, M.D.	Genetic	Part-time
13.	Chanin Limwongse, M.D.	Genetic	Part-time
14.	Surachat Chakrapee-Sirisuk, M.D.	Medical oncologist	Full-time
15.	Surachai Sitawarin, M.D.	Medical oncologist	Full-time
16.	Chatchai Koowattanapaisan, M.D.	Medical oncologist	Full-time
17.	Kanoknid Limvipaveanan, M.D.	Medical oncologist	Full-time
18.	Titima Purvaranukroh, M.D.	Medical oncologist	Full-time
19.	Natchadol Kittiwarat, M.D.	Medical oncologist	Full-time
20.	Kunlatida Maneenil, M.D.	Medical oncologist	Part-time
21.	Narin Vorawuth, M.D.	Medical oncologist	Part-time
22.	Vichien Srimuninnimit, M.D.	Medical oncologist	Part-time
23.	Sumitra Thongprasert, M.D.	Medical oncologist	Full-time
24.	Thiva Kiatpanabhikul, M.D.	Medical oncologist	Part-time
25.	Chanida Vinayanuwattikun, M.D.	Medical oncologist	Part-time
26.	Prasert Lertsanguansinchai, M.D.	Radiation oncologist	Full-time
27.	Sakpisid Nawasiri, M.D.	Radiation oncologist	Full-time
28.	Chanawat Tesavibul, M.D.	Radiation oncologist	Full-time
29.	Sirikanya Chongsatienttham, M.D.	Radiation oncologist	Full-time
30.	Chonlakiet Khorprasert, M.D.	Radiation oncologist	Part-time
31.	Napapat Amornwichet, M.D.	Radiation oncologist	Part-time
32.	Nantakan Ieumwananthachai, M.D.	Radiation oncologist	Part-time
33.	Saipin Tangkaratt, M.D.	Radiation oncologist	Part-time
34.	Parmon Puddhikarant, M.D.	Radiation oncologist	Part-time
35.	Nithinai Tangprasert, M.D.	Radiation oncologist	Part-time
36.	Danita Kannarumimit, M.D.	Radiation oncologist	Part-time
37.	Pathomphorn Siraprasasiri, M.D.	Radiation oncologist	Part-time
38.	Ladawan Narkwong, M.D.	Radiation oncologist	Part-time
39.	Yongyut Kongthanasat, M.D.	Radiation oncologist	Part-time
40.	Apiradee Kridakara, M.D.	Radiation oncologist	Part-time
41.	Attapol Pinitpatcharalert, M.D.	Radiation oncologist	Part-time
42.	Kanokpis Townamchai, M.D.	Radiation oncologist	Part-time
43.	Kitwadee S. Athigakunagorn, M.D.	Radiation oncologist	Part-time
44.	Pornsri Kidchob, M.D.	Radiation oncologist	Full-time

No.	NAME	SPECIALTY	REMARK
45.	Viruch Chareoniam, M.D.	Gynecologic oncologist	Full-time
46.	Sosakul Bunyaviroch, M.D.	Gynecologic oncologist	Part-time
47.	Phanont Kasemsan, M.D.	Gynecologic oncologist	Part-time
48.	Chantawat Sheanakul, M.D.	Gynecologic oncologist	Part-time
49.	Siriwan Tangitgamol, M.D.	Gynecologic oncologist	Part-time
50.	Laksamee Chanvej, M.D.	Pain & Palliative	Full-time
51.	Boonthida Chaidaroon, M.D.	Pain & Palliative	Part-time
52.	Watanya Chaiwong, M.D.	Pain & Palliative	Part-time
53.	Samart Rajchadara, M.D.	Nuclear medicine	Full-time
54.	Tawatchai Chaiwatanarat, M.D.	Nuclear medicine	Part-time
55.	Apakorn Kositwattanalerk, M.D.	Nuclear medicine	Part-time
56.	Supatporn Tepmongkol, M.D.	Nuclear medicine	Part-time
57.	Chanisa Chotipanic, M.D.	Nuclear medicine	Part-time
58.	Nantiya Chantarapitak, M.D.	Nuclear medicine	Part-time
59.	Trirat Boonya-ussadorn, M.D.	Nuclear medicine	Part-time
60.	Usanee Vutrapongwatana, M.D.	Nuclear medicine	Part-time
61.	Komgrit Tanisaro, M.D.	Interventional Radiologist	Full-time
62.	Wachira Jarungkiattikhajorn, M.D.	Interventional Radiologist	Part-time
63.	Piyasak Thaharavanich, M.D.	Breast surgeon	Full-time
64.	Kris Bhothisuwan, M.D.	Breast surgeon	Part-time
65.	Supakorn Rojananin, M.D.	Breast surgeon	Part-time
66.	Poramaporn Prasarttong-Osoth, M.D.	Breast surgeon	Part-time
67.	Pongthep Pisarnaturakit, M.D.	Breast surgeon	Part-time
68.	Suebwong Chuthapisith, M.D.	Breast surgeon	Part-time
69.	Satit Srimontayamas, M.D.	Breast surgeon	Part-time
70.	Poonpissamai Suwajo, M.D.	Breast surgeon	Part-time
71.	Dolrudee Songtish, M.D.	Breast surgeon	Part-time
72.	Sasithorn Sujarittanakarn, M.D.	Breast surgeon	Part-time
73.	Sirimana Ratanaprakarn, M.D.	Radiologist	Full-time
74.	Natthaphum Kanchanaporn, M.D.	Radiologist	Full-time
75.	Kewalee Sasiwimonphan, M.D.	Radiologist	Part-time
76.	Tanaphon Maipang, M.D.	Surgical oncologist	Full-time
77.	Art Hiranyakas, M.D.	Surgical oncologist	Full-time
78.	Duangdao Sahakitrungruang, M.D.	Breast Radiologist	Part-time
79.	Napapat Viravan, M.D.	Breast Radiologist	Part-time
80.	Naruporn Marukatat, M.D.	Breast Radiologist	Part-time
81.	Pornpim Korpraphong, M.D.	Breast Radiologist	Part-time
82.	Wiluck Chu-Ongsakul, M.D.	Breast Radiologist	Part-time
83.	Wilaiporn Bhothisuwan, M.D.	Breast Radiologist	Part-time
84.	Sirirat Teavirat, M.D.	Breast Radiologist	Part-time
85.	Niramol Pantawanun, M.D.	Breast Radiologist	Part-time
86.	Kwansakul Boonsararuxapong, M.D.	Breast Radiologist	Part-time
87.	Lertlakana Bhoopat, M.D.	Internal medicine	Full-time